Phathom Pharmaceuticals, Inc. announced today that members of its management team are scheduled to participate in the following investor conferences in November.
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in November:
Guggenheim Securities 5th Annual Inflammation, Neurology & Immunology Conference in New York, NY
Date: Tuesday, November 7, 2023
Live Webcast: 2:30 p.m. ET
Management to participate in one-on-one meetings throughout the conference
Jefferies London Healthcare Conference in London, England
Date: Tuesday, November 14, 2023
Live Webcast: 10:30 a.m. ET
Management to participate in one-on-one meetings throughout the conference
Stifel 2023Healthcare Conference in New York, NY
Date: Wednesday, November 15, 2023
Live Webcast: 2:25 p.m. ET
Management to participate in one-on-one meetings throughout the conference
Craig-Hallum 14th Annual Alpha Select Conference in New York, NY
Date: Thursday, November 16, 2023
Management to participate in one-on-one meetings throughout the conference
Evercore ISI 6th Annual HealthCONx Conference in Miami, FL
Date: Wednesday, November 29, 2023
Live Webcast: 4:15 p.m. ET
Management to participate in one-on-one meetings throughout the conference
To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2023 Phathom Pharmaceuticals. All rights reserved.
